A 24 Week Phase IIIb/IV Single Arm Open Label Observational Study to Explore the Efficacy of Protease Inhibitors Given in Combination With Reverse Transcriptase Inhibitors to HIV-1 Infected Subjects With Protease Mutations Selected During Therapy With GW433908 Containing Antiretroviral Therapy.
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Fosamprenavir (Primary) ; HIV protease inhibitors; HIV reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- 23 Nov 2005 New trial record.